187 related articles for article (PubMed ID: 7758235)
1. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
[TBL] [Abstract][Full Text] [Related]
2. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
van der Lely AJ; Harris AG; Lamberts SW
Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients.
Yang I; Park S; Ryu M; Woo J; Kim S; Kim J; Kim Y; Choi Y
Eur J Endocrinol; 1996 Jun; 134(6):720-6. PubMed ID: 8766942
[TBL] [Abstract][Full Text] [Related]
4. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone responses to the releasing hormones GHRH and GnRH and the inhibitors somatostatin and bromocriptine in TRH-responsive and non-responsive acromegalics.
Smals AE; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
Acta Endocrinol (Copenh); 1987 Sep; 116(1):53-8. PubMed ID: 2889308
[TBL] [Abstract][Full Text] [Related]
6. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
Watanobe H; Tamura T; Sasaki S; Takebe K
Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
[TBL] [Abstract][Full Text] [Related]
7. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
8. [The relationship between TSH response to TRH and GH response to dopaminergic agents in patients with acromegaly].
Tokuyama T; Yoshinari M; Okamura K; Ikenoue H; Sato K; Kuroda T; Fujishima M
Nihon Naibunpi Gakkai Zasshi; 1991 Feb; 67(2):65-74. PubMed ID: 1674920
[TBL] [Abstract][Full Text] [Related]
9. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
[TBL] [Abstract][Full Text] [Related]
10. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
Gasińska T; Nowak S
Endokrynol Pol; 1993; 44(4):455-65. PubMed ID: 8055814
[TBL] [Abstract][Full Text] [Related]
11. Gsp mutation in acromegaly and its influence on TRH-induced paradoxical GH response.
Goto Y; Kinoshita M; Oshino S; Arita H; Kitamura T; Otsuki M; Shimomura I; Yoshimine T; Saitoh Y
Clin Endocrinol (Oxf); 2014 May; 80(5):714-9. PubMed ID: 24111551
[TBL] [Abstract][Full Text] [Related]
12. The higher the growth hormone response to growth hormone releasing hormone the lower the response to bromocriptine and thyrotrophin releasing hormone in acromegaly.
Smals AE; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
Clin Endocrinol (Oxf); 1987 Jul; 27(1):43-7. PubMed ID: 3115634
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly.
Watanobe H; Tamura T
Neuropeptides; 1995 Feb; 28(2):115-24. PubMed ID: 7746355
[TBL] [Abstract][Full Text] [Related]
14. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
[TBL] [Abstract][Full Text] [Related]
15. Mammosomatotroph adenoma causing gigantism in an 8-year old boy: a possible pathogenetic mechanism.
Dubuis JM; Deal CL; Drews RT; Goodyer CG; Lagacé G; Asa SL; Van Vliet G; Collu R
Clin Endocrinol (Oxf); 1995 May; 42(5):539-49. PubMed ID: 7621575
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
[TBL] [Abstract][Full Text] [Related]
17. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
Haraguchi K; Ohtaka M; Takazawa K; Endo T; Onaya T
Endocr J; 1995 Apr; 42(2):295-300. PubMed ID: 7627275
[TBL] [Abstract][Full Text] [Related]
18. GS protein mutations and pituitary tumors: functional correlates and possible therapeutic implications.
Faglia G; Arosio M; Spada A
Metabolism; 1996 Aug; 45(8 Suppl 1):117-9. PubMed ID: 8769403
[TBL] [Abstract][Full Text] [Related]
19. Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies.
Colao A; Merola B; Ferone D; Calabrese MR; Longobardi S; Spaziante R; Di Renzo G; Annunziato L; Lombardi G
Eur J Endocrinol; 1994 Jul; 131(1):14-9. PubMed ID: 8038903
[TBL] [Abstract][Full Text] [Related]
20. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
